Kalo Z - Search Results

1

Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries.

Tachkov K, Zemplenyi A, Kamusheva M, Dimitrova M, Siirtola P, Pontén J, Nemeth B, Kalo Z, Petrova G. Tachkov K, et al. Among authors: kalo z. Front Public Health. 2022 Jul 14;10:921226. doi: 10.3389/fpubh.2022.921226. eCollection 2022. Front Public Health. 2022. PMID: 35910914 Free PMC article.

2

Health technology assessment: a European collaboration.

Kaló Z, Vokó Z. Kaló Z, et al. Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):41-3. doi: 10.1586/erp.10.90. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 21351855

3

Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries.

Kaló Z, Landa K, Doležal T, Vokó Z. Kaló Z, et al. Eur J Cancer Care (Engl). 2012 Jul;21(4):442-9. doi: 10.1111/j.1365-2354.2012.01351.x. Epub 2012 Apr 18. Eur J Cancer Care (Engl). 2012. PMID: 22510226

4

Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology.

Inotai A, Pékli M, Jóna G, Nagy O, Remák E, Kaló Z. Inotai A, et al. Among authors: kalo z. BMC Health Serv Res. 2012 Sep 21;12:332. doi: 10.1186/1472-6963-12-332. BMC Health Serv Res. 2012. PMID: 22999574 Free PMC article. Review.

5

Benefits of investment into modern medicines in Central-Eastern European countries.

Inotai A, Petrova G, Vitezic D, Kaló Z. Inotai A, et al. Among authors: kalo z. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):71-9. doi: 10.1586/14737167.2014.868314. Epub 2013 Dec 19. Expert Rev Pharmacoecon Outcomes Res. 2014. PMID: 24350863 Review.

6

HTA Implementation Roadmap in Central and Eastern European Countries.

Kaló Z, Gheorghe A, Huic M, Csanádi M, Kristensen FB. Kaló Z, et al. Health Econ. 2016 Feb;25 Suppl 1(Suppl Suppl 1):179-92. doi: 10.1002/hec.3298. Epub 2016 Jan 14. Health Econ. 2016. PMID: 26763688 Free PMC article.

7

[A microcost analysis of radiation therapy of localized prostate cancer].

Zemplényi AT, Mangel L, Kaló Z, Endrei D, Boncz I. Zemplényi AT, et al. Among authors: kalo z. Orv Hetil. 2016 Mar 20;157(12):461-8. doi: 10.1556/650.2016.30392. Orv Hetil. 2016. PMID: 26971646 Hungarian.

8

[Meta-analysis of the side-effect profiles of modern radiation therapies for patients with prostate cancer].

Zemplényi AT, Mangel L, Kaló Z, Endrei D, Lohner S, Boncz I. Zemplényi AT, et al. Among authors: kalo z. Orv Hetil. 2016 May 15;157(20):776-88. doi: 10.1556/650.2016.30422. Orv Hetil. 2016. PMID: 27156525 Hungarian.

9

Comparative Cost-Effectiveness Study of Modern Radiation Therapies in Hungary for Localized Prostate Cancer.

Zemplényi A, Kalo Z, Mangel L, Endrei D, Boncz I. Zemplényi A, et al. Among authors: kalo z. Value Health. 2014 Nov;17(7):A636. doi: 10.1016/j.jval.2014.08.2282. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202266 Free article. No abstract available.

10

Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.

Zelei T, Molnár MJ, Szegedi M, Kaló Z. Zelei T, et al. Among authors: kalo z. Orphanet J Rare Dis. 2016 Jun 4;11(1):72. doi: 10.1186/s13023-016-0455-6. Orphanet J Rare Dis. 2016. PMID: 27259284 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

188 results

Search Page

Filters